Announced details
Ophthalmology, corneal epithelial stem cell exhaustion, corneal scarring
A business partner. The companies have established a cooperative framework for sharing safety information on recombinant human dHGF protein and optimizing the manufacturing process.
A privately held biotech venture originating from Harvard University in the United States. It is advancing drug development of recombinant human dHGF protein in ophthalmology and conducting clinical trials in the United States for corneal epithelial stem cell exhaustion and corneal scarring.
San Francisco Bay Area, California (South San Francisco)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Press release by Claris Biotherapeutics (https://www.clarisbio.com/news/press-releases/09-24-2026/)
| Item | Details |
|---|---|
| Names of Products / Services Covered | oremepermin alfa (オレメペルミン アルファ, recombinant human dHGF protein) |
| Counterparty | Claris Biotherapeutics |
| Counterparty overview | A privately held biotech venture originating from Harvard University in the United States. It is advancing drug development of recombinant human dHGF protein in ophthalmology and conducting clinical trials in the United States for corneal epithelial stem cell exhaustion and corneal scarring. |
| Relationship with the Company | A business partner. The companies have established a cooperative framework for sharing safety information on recombinant human dHGF protein and optimizing the manufacturing process. |
| Launch date | First half of 2027 (planned start of pivotal trial) |
| Applicable area | Ophthalmology, corneal epithelial stem cell exhaustion, corneal scarring |
| Location | San Francisco Bay Area, California (South San Francisco) |
| Source | Press release by Claris Biotherapeutics (https://www.clarisbio.com/news/press-releases/09-24-2026/) |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To accelerate collaboration with pharmaceutical companies, biotech ventures, investors and research institutions concentrated in the San Francisco Bay Area, as well as the recruitment of outstanding talent and the strengthening of its business platform.